Piracetam for the treatment of sickle cell disease in children- a double blind test

Mohsen A F El-Hazmi1, I Al-Fawaz, A Warsy

  • 1Medical Biochemistry Department & Collaborating Center, College of Medicine, King Khalid Hospital, Riyadh, Kingdom of Saudi Arabia.

Saudi Medical Journal
|October 5, 2016
PubMed

Insights

This study is unavailable in digital format. Full text is only accessible as a scanned copy of the original print version.

Area of Science:

  • This study falls under the category of general medicine.
  • The research focuses on medical information accessibility.

Background:

  • Access to full-text medical literature is crucial for research and clinical practice.
  • Digital formats have become the standard for disseminating scientific information.

Purpose of the Study:

  • To inform readers about the accessibility of the full text of this article.
  • To indicate that the full text is available only as a scanned print version.

Main Methods:

  • The study's method is to provide a notice regarding the format of the full text.
  • No specific research methodology was applied beyond this notification.

Main Results:

  • The full text of the article is not available in a digital format.
  • Access is limited to a scanned copy of the original print version.

Conclusions:

  • Researchers and clinicians should be aware of the format limitations for accessing this article.
  • Alternative access methods or formats are not provided.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
349
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
309